About RapiDx
RapiDx is a company based in Tel Aviv (Israel) founded in 2008. RapiDx has raised $1 million across 1 funding round from investors including TechnoPlus Ventures and Medvest. RapiDx operates in a competitive market with competitors including Souzhou Ribo Life Science, PathoQuest, Quantalife, Chembio and Senzo, among others.
- Headquarter Tel Aviv, Israel
- SectorsHealthcare
- Phone•••• ••••
- Website rapidx.co.il
- Total Equity Funding$1M (USD)
in 1 rounds
- Latest Funding Round$1M (USD), Seed
Jul 2008
- InvestorsTechnoPlus Ventures
& 1 more
Funding Insights of RapiDx
RapiDx has successfully raised a total of $1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1 million completed in July 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1M
- Total Rounds 1
- Last Round Seed — $1M
- First Round $1M
(Jul 2008)
- Investors Count 2
All 1 funding rounds of RapiDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2008 | $1M | Seed | – | TechnoPlus Ventures, Medvest | – |
2 investors in total: 2 institutional.
Investors in RapiDx
RapiDx has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include TechnoPlus Ventures and Medvest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage companies in Israel are invested in by TechnoPlus Ventures. | 1997 | technoplusvc.com | Tel Aviv, Israel | |
- | – | medvest.co.uk | - |
Investor details for RapiDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of RapiDx
2 dated milestones of RapiDx, from founding to its latest funding, stage changes and deals.
- Founded RapiDx is founded.
- Funding First funding round of $1.0M.
Competitors of RapiDx
RapiDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Souzhou Ribo Life Science, PathoQuest, Quantalife, Chembio and Senzo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ribolia.com | 2007 | Suzhou, China | $200.79M | – | Nucleic acid drugs are developed via RNA interference technology. | |
| pathoquest.com | 2010 | Paris, France | $9.99M | – | Next-generation sequencing is provided for microbiology testing applications. | |
| quantalife.com | 2008 | Pleasanton, United States | $28.71M | – | Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. | |
| chembio.com | 1986 | Medford, United States | – | 213 | Proprietary immunoassay platform is utilized for infectious disease diagnostics. | |
| senzo.com | 2013 | San Francisco, United States | $9.6M | 13 | Point-of-care diagnostic devices for infectious diseases are developed. | |
| hememics.com | 2009 | Gaithersburg, United States | $4.6M | 13 | Biopreservation platform for mammalian cells and biologics is developed. | |
| daktaridx.com | 2008 | Boston, United States | $73.42M | 23 | Point of care diagnostic platform and data management system | |
| e25bio.com | 2018 | Cambridge, United States | $4.8M | 5 | Diagnostic platform for disease detection and mapping is provided. | |
| matridx.com | 2019 | Hangzhou, China | – | – | Sequencing-based platform for microorganism detection in patients is developed. |
Detailed competitors of RapiDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to RapiDx
10 companies that operate in the same segment as RapiDx (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RapiDx
RapiDx was founded in 2008.
RapiDx is headquartered in Tel Aviv, Israel.
RapiDx is a funded company, having raised a total of $1M across 1 funding round to date. The company's 1st funding round was a Seed of $1M, raised on Jul 2008.
RapiDx was founded in 2008 in Tel Aviv, Israel, within the diagnostics sector. Self-testing platforms for detecting health conditions are developed, with operations centered on point-of-care solutions. The flagship RapTest is designed for HIV detection, while the pipeline encompasses tests for malaria, troponin levels, and cholesterol. The companys domain, rapidx.co.il, supports these activities in the health testing field.
RapiDx's top competitors include Souzhou Ribo Life Science, Chembio and Quantalife.
RapiDx has 2 investors. Key investors include TechnoPlus Ventures, and Medvest.